A landmark meta-analysis conducted for the World Health Organisation was published in JAMA this week, reporting that corticosteroid use improves survival in critically ill patients with COVID-19. The analysis pooled the results of seven randomised controlled trials (1703 participants), including the world-first, Australian-led REMAP-CAP platform trial which was published concurrently.
The Disease-Modifying Treatments and Chemoprophylaxis Panel is currently reviewing the data to incorporate this important new evidence into Taskforce guidance.